Top

Archive | current researcher

Lindsley, R. Coleman, M.D., Ph.D.

R. Coleman Lindsley, M.D., Ph.D. Dana-Farber Cancer Institute 2016 Grant Recipient The context-dependent role of BCOR mutations in MDS pathogenesis EvansMDS Research Grant 2016 PROJECT SUMMARY MDS is a heterogeneous disease, with diverse manifestations and an unpredictable clinical course. In part, the differences between patients can be attributed to the particular combination of mutations the [...]
Continue Reading

Halene, Stephanie, M.D., Ph.D. 2016

Study of MDS Biology and Response to Targeted Therapeutics in a MDS Xenotransplantation Model Stephanie Halene M.D., Ph.D. Yale University School of Medicine 2016 Grant Recipient Study of MDS Biology and Response to Targeted Therapeutics in a MDS Xenotransplantation Model EvansMDS Discovery Research Grant 2016 PROJECT SUMMARY Patients with myelodysplasia (MDS) suffer from bone marrow [...]
Continue Reading

Jordan, Craig T. Ph.D. 2016

Adoptive CD123 CAR T-cell therapy for the treatment of myelodysplastic syndrome Craig T. Jordan, Ph.D. University of Colorado Denver 2016 Grant Recipient Adoptive CD123 CAR T-cell therapy for the treatment of myelodysplastic syndrome EvansMDS Translational Research Grant 2016 PROJECT SUMMARY Myelodysplastic Syndromes (MDS) are a group of bone marrow disorders where abnormal cells replace the [...]
Continue Reading

Abdel-Wahab, Omar 2016

Omar Abdel-Wahab Memorial Sloan-Kettering Cancer Center 2016 Grant Recipient Biology and Therapeutic Targeting of Spliceosome-Mutant MDS: Elucidating Critical Targets, Transcripts, and Collaborating Events in Spliceosomal-Mutant MDS EvansMDS Programmatic Research Grant 2016 PROJECT SUMMARY Patients with myelodysplastic syndromes (MDS) are prone to infection, bleeding, and fatigue (as a consequence of low blood counts) and are at [...]
Continue Reading

Papaemmanuil, Elli, Ph.D.

Biological Consequences of SF3B1 mutations in MDS Elli Papaemmanuil, Ph.D. Memorial Sloan-Kettering Cancer Center 2016 Grant Recipient Biological Consequences of SF3B1 mutations in MDS EvansMDS Discovery Research Grant 2016 PROJECT SUMMARY Myelodysplasia (MDS) is a prevalent blood cancer that affects the cells in the bone marrow that normally sustain blood formation, called hematopoietic stem cells [...]
Continue Reading

Look, Thomas A., M.D.

Identification of drugs that are in Phase I/II clinical trials or FDA-approved that are selectively active in MDS cases with inactivating mutations of TET2 Thomas A. Look, M.D. Dana-Farber Cancer Institute 2016 Grant Recipient Identification of drugs that are in Phase I/II clinical trials or FDA-approved that are selectively active in MDS cases with inactivating [...]
Continue Reading

Graubert,, Timothy A., M.D. 2016

Biology and Therapeutic Targeting of Spliceosome-Mutant MDS: Identification of Therapeutic Vulnerabilities in Spliceosomal-Mutant MDS Timothy A. Graubert, M.D. Massachusetts General Hospital Cancer Center 2016 Grant Recipient Biology and Therapeutic Targeting of Spliceosome-Mutant MDS: Identification of Therapeutic Vulnerabilities in Spliceosomal-Mutant MDS EvansMDS Programmatic Research Grant 2016 PROJECT SUMMARY Patients with myelodysplastic syndromes (MDS) are prone to [...]
Continue Reading

Walter, Matthew J., M.D. 2016

Biology and Therapeutic Targeting of Spliceosome-Mutant MDS: Identification of Cooperating Events Contributing to Spliceosomal-Mutant MDS Matthew J. Walter, M.D. Washington University 2016 Grant Recipient Biology and Therapeutic Targeting of Spliceosome-Mutant MDS: Identification of Cooperating Events Contributing to Spliceosomal-Mutant MDS EvansMDS Programmatic Research Grant 2016 PROJECT SUMMARY Patients with myelodysplastic syndromes (MDS) are prone to infection, [...]
Continue Reading

Challen, Grant A., Ph.D.

Targeting the Pathogenic Epigenome in MDS Grant A. Challen, Ph.D Washington University 2016 Grant Recipient Targeting the Pathogenic Epigenome in MDS EvansMDS Discovery Research Grant 2016 PROJECT SUMMARY Epigenetics refers to changes in gene expression that does not involve changes to the underlying DNA sequence: a change in phenotype without a change in genotype. Epigenetic [...]
Continue Reading

Kielkopf, Clara, Ph.D.

Structural mechanisms and targeting of MDS-relevant pre-mRNA splicing factors Clara Kielkopf, Ph.D. University of Rochester 2016 Grant Recipient Structural mechanisms and targeting of MDS-relevant pre-mRNA splicing factors PROJECT SUMMARY More than 60,000 patients with myelodysplastic syndromes (MDS) reside in the United States. These MDS patients suffer from anemia and abnormal blood cell production. While such [...]
Continue Reading